26
|
Wehle S, Niebuhr C, Yashchenko S, Adachi I, Aihara H, Al Said S, Asner DM, Aulchenko V, Aushev T, Ayad R, Aziz T, Babu V, Bakich AM, Bansal V, Barberio E, Bartel W, Behera P, Bhuyan B, Biswal J, Bobrov A, Bondar A, Bonvicini G, Bozek A, Bračko M, Browder TE, Červenkov D, Chang P, Chekelian V, Chen A, Cheon BG, Chilikin K, Chistov R, Cho K, Choi Y, Cinabro D, Dash N, Dingfelder J, Doležal Z, Drásal Z, Dutta D, Eidelman S, Epifanov D, Farhat H, Fast JE, Ferber T, Fulsom BG, Gaur V, Gabyshev N, Garmash A, Gillard R, Goldenzweig P, Golob B, Grzymkowska O, Guido E, Haba J, Hara T, Hayasaka K, Hayashii H, Hedges MT, Hou WS, Hsu CL, Iijima T, Inami K, Inguglia G, Ishikawa A, Itoh R, Iwasaki Y, Jacobs WW, Jaegle I, Jeon HB, Jin Y, Joffe D, Joo KK, Julius T, Kaliyar AB, Kang KH, Karyan G, Katrenko P, Kawasaki T, Kichimi H, Kiesling C, Kim DY, Kim HJ, Kim JB, Kim KT, Kim MJ, Kim SH, Kinoshita K, Koch L, Kodyš P, Korpar S, Kotchetkov D, Križan P, Krokovny P, Kuhr T, Kulasiri R, Kumita T, Kuzmin A, Kwon YJ, Lange JS, Li CH, Li L, Li Y, Li Gioi L, Libby J, Liventsev D, Lubej M, Luo T, Masuda M, Matsuda T, Miyabayashi K, Miyake H, Mizuk R, Mohanty GB, Mori T, Mussa R, Nakano E, Nakao M, Nanut T, Nath KJ, Natkaniec Z, Nayak M, Nisar NK, Nishida S, Ogawa S, Ono H, Onuki Y, Pakhlova G, Pal B, Park CS, Park CW, Park H, Paul S, Pesántez L, Piilonen LE, Pulvermacher C, Rauch J, Ritter M, Rostomyan A, Sakai Y, Sandilya S, Santelj L, Sanuki T, Sato Y, Savinov V, Schlüter T, Schneider O, Schnell G, Schwanda C, Schwartz AJ, Seino Y, Senyo K, Seon O, Seong IS, Sevior ME, Shen CP, Shibata TA, Shiu JG, Shwartz B, Simon F, Sinha R, Solovieva E, Starič M, Strube JF, Sumisawa K, Sumiyoshi T, Takizawa M, Tamponi U, Tenchini F, Trabelsi K, Tsuboyama T, Uchida M, Uglov T, Unno Y, Uno S, Urquijo P, Ushiroda Y, Usov Y, Vahsen SE, Van Hulse C, Varner G, Varvell KE, Vorobyev V, Vossen A, Waheed E, Wang CH, Wang MZ, Wang P, Watanabe M, Watanabe Y, Widmann E, Williams KM, Won E, Yamamoto H, Yamashita Y, Ye H, Yook Y, Yuan CZ, Yusa Y, Zhang ZP, Zhilich V, Zhukova V, Zhulanov V, Ziegler M, Zupanc A. Lepton-Flavor-Dependent Angular Analysis of B→K^{*}ℓ^{+}ℓ^{-}. PHYSICAL REVIEW LETTERS 2017; 118:111801. [PMID: 28368653 DOI: 10.1103/physrevlett.118.111801] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Indexed: 06/07/2023]
Abstract
We present a measurement of angular observables and a test of lepton flavor universality in the B→K^{*}ℓ^{+}ℓ^{-} decay, where ℓ is either e or μ. The analysis is performed on a data sample corresponding to an integrated luminosity of 711 fb^{-1} containing 772×10^{6} BB[over ¯] pairs, collected at the ϒ(4S) resonance with the Belle detector at the asymmetric-energy e^{+}e^{-} collider KEKB. The result is consistent with standard model (SM) expectations, where the largest discrepancy from a SM prediction is observed in the muon modes with a local significance of 2.6σ.
Collapse
|
27
|
Lindeman GJ, Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB, kConFab C, Rohrbach K, Huang LY, Soriano R, Smyth GK, Dougall WC, Visvader JE. Abstract S2-04: RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-s2-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: BRCA1 mutation carriers commonly undergo prophylactic mastectomy to reduce their risk of breast cancer. The precise role of chemoprevention with tamoxifen, which reduces the incidence of ER-positive breast cancer in the general population, is uncertain for BRCA1 mutation carriers, where uptake has been modest. The identification of an effective and acceptable prevention therapy therefore remains a 'holy grail' for the field. Precancerous BRCA1mut/+ tissue harbors an aberrant population of luminal progenitor cells and deregulated progesterone signaling has been implicated in BRCA1-associated oncogenesis. Since Receptor Activator of Nuclear Factor-kappa B ligand (RANKL) is a key paracrine effector of progesterone signaling, and RANKL and its receptor RANK contribute to mammary tumorigenesis, we investigated a role for this pathway in the preneoplastic phase of BRCA1 mutation carriers.
Methods: We explored a role for the RANK/RANKL pathway during the preneoplastic phase in freshly isolated (histologically normal) patient specimens from BRCA1 mutation carriers using several approaches. RANK and RANKL expression in breast cancer was evaluated in formalin fixed paraffin embedded (FFPE) archival sections by IHC from the kConFab and the Amgen Tissue Banks. All samples were obtained with patient consent and relevant IRB approval. A role for RANKL inhibition in attenuating tumor onset was studied using the MMTV-cre/Brca1fl/fl/p53+/– mouse model that recapitulates human basal-like breast cancer.
Results: We identified two subsets of luminal progenitors (RANK+ and RANK–) in histologically normal tissue of BRCA1 mutation carriers and found that RANK+ cells are highly proliferative, exhibit grossly aberrant DNA repair and bear a molecular signature similar to that of basal-like breast cancer. Moreover, high levels of RANK expression prevailed in established BRCA1-associated tumors. These data suggest that RANK+ and not RANK– progenitors are a key target population in these women. Notably, inhibition of RANKL signaling by denosumab in 3D breast organoids derived from pre-neoplastic BRCA1mut/+ tissue attenuated progesterone-induced proliferation. Furthermore, inhibition of RANKL with either the RANKL inhibitor OPG-Fc or a RANKL monoclonal antibody in a Brca1-deficient mouse model significantly curtailed mammary tumorigenesis, when compared to controls (p<0.001).
Conclusions: Together these findings identify a targetable pathway in a putative cell of origin population in BRCA1 mutation carriers and implicate RANKL blockade as a promising breast cancer prevention strategy.
Citation Format: Lindeman GJ, Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB, kConFab Consortium, Rohrbach K, Huang L-Y, Soriano R, Smyth GK, Dougall WC, Visvader JE. RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr S2-04.
Collapse
|
28
|
Nanut T, Zupanc A, Adachi I, Aihara H, Al Said S, Asner DM, Aulchenko V, Aushev T, Ayad R, Babu V, Badhrees I, Bakich AM, Bansal V, Behera P, Bhardwaj V, Biswal J, Bondar A, Bozek A, Bračko M, Browder TE, Červenkov D, Chekelian V, Chen A, Cheon BG, Chistov R, Cho K, Choi SK, Choi Y, Cinabro D, Dash N, Di Carlo S, Doležal Z, Dutta D, Eidelman S, Farhat H, Fast JE, Ferber T, Fulsom BG, Gaur V, Gabyshev N, Garmash A, Gillard R, Goldenzweig P, Golob B, Hayasaka K, Hayashii H, Hou WS, Iijima T, Inami K, Inguglia G, Ishikawa A, Iwasaki Y, Jacobs WW, Jaegle I, Joffe D, Joo KK, Julius T, Kaliyar AB, Kang KH, Kawasaki T, Kim DY, Kim JB, Kim KT, Kim MJ, Kim SH, Kinoshita K, Kodyš P, Korpar S, Krokovny P, Kuhr T, Kulasiri R, Kuzmin A, Kwon YJ, Lange JS, Lee IS, Li CH, Li L, Li Y, Li Gioi L, Libby J, Liventsev D, Lubej M, Masuda M, Matsuda T, Matvienko D, Miyabayashi K, Miyata H, Mizuk R, Mohanty GB, Moon HK, Nakao M, Nath KJ, Nayak M, Nisar NK, Nishida S, Ogawa S, Okuno S, Pakhlov P, Pakhlova G, Pal B, Park CS, Park CW, Park H, Paul S, Pedlar TK, Pesántez L, Pestotnik R, Petrič M, Piilonen LE, Prasanth K, Pulvermacher C, Rauch J, Ritter M, Rostomyan A, Sakai Y, Sandilya S, Santelj L, Sanuki T, Sato Y, Savinov V, Schlüter T, Schneider O, Schnell G, Schwanda C, Schwartz AJ, Seino Y, Senyo K, Seon O, Sevior ME, Shebalin V, Shen CP, Shibata TA, Shiu JG, Shwartz B, Solovieva E, Stanič S, Starič M, Strube JF, Stypula J, Sumiyoshi T, Takizawa M, Tamponi U, Tenchini F, Trabelsi K, Uchida M, Uno S, Ushiroda Y, Varner G, Vinokurova A, Vorobyev V, Vossen A, Wang CH, Wang MZ, Wang P, Watanabe Y, Widmann E, Won E, Yamaoka J, Yamashita Y, Yelton J, Zhang ZP, Zhilich V, Zhukova V, Zhulanov V. Observation of D^{0}→ρ^{0}γ and Search for CP Violation in Radiative Charm Decays. PHYSICAL REVIEW LETTERS 2017; 118:051801. [PMID: 28211706 DOI: 10.1103/physrevlett.118.051801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Indexed: 06/06/2023]
Abstract
We report the first observation of the radiative charm decay D^{0}→ρ^{0}γ and the first search for CP violation in decays D^{0}→ρ^{0}γ, ϕγ, and K[over ¯]^{*0}(892)γ, using a data sample of 943 fb^{-1} collected with the Belle detector at the KEKB asymmetric-energy e^{+}e^{-} collider. The branching fraction is measured to be B(D^{0}→ρ^{0}γ)=(1.77±0.30±0.07)×10^{-5}, where the first uncertainty is statistical and the second is systematic. The obtained CP asymmetries A_{CP}(D^{0}→ρ^{0}γ)=+0.056±0.152±0.006, A_{CP}(D^{0}→ϕγ)=-0.094±0.066±0.001, and A_{CP}(D^{0}→K[over ¯]^{*0}γ)=-0.003±0.020±0.000 are consistent with no CP violation. We also present an improved measurement of the branching fractions B(D^{0}→ϕγ)=(2.76±0.19±0.10)×10^{-5} and B(D^{0}→K[over ¯]^{*0}γ)=(4.66±0.21±0.21)×10^{-4}.
Collapse
|
29
|
Mizuk R, Bondar A, Adachi I, Aihara H, Asner DM, Atmacan H, Aulchenko V, Aushev T, Ayad R, Badhrees I, Bakich AM, Barberio E, Behera P, Bhardwaj V, Bhuyan B, Biswal J, Bobrov A, Bonvicini G, Bozek A, Bračko M, Browder TE, Červenkov D, Chekelian V, Chen A, Cheon BG, Chilikin K, Chistov R, Chobanova V, Choi SK, Choi Y, Cinabro D, Dalseno J, Danilov M, Dash N, Doležal Z, Drutskoy A, Eidelman S, Epifanov D, Ferber T, Fulsom BG, Gaur V, Garmash A, Gillard R, Goh YM, Goldenzweig P, Golob B, Greenwald D, Hara T, Hayasaka K, Hayashii H, Hou WS, Hsu CL, Inami K, Inguglia G, Ishikawa A, Iwasaki Y, Jaegle I, Julius T, Kang KH, Katrenko P, Kim DY, Kim HJ, Kim JB, Kim KT, Kim MJ, Kim SH, Kim YJ, Kinoshita K, Kodyš P, Korpar S, Kotchetkov D, Krokovny P, Kuhr T, Kuzmin A, Kwon YJ, Lange JS, Li CH, Li H, Li L, Li Gioi L, Libby J, Liventsev D, Lubej M, Luo T, Masuda M, Matsuda T, Matvienko D, Miyabayashi K, Miyata H, Mohanty GB, Moll A, Nakano E, Nakao M, Nanut T, Nath KJ, Negishi K, Niiyama M, Nisar NK, Nishida S, Ogawa S, Okuno S, Olsen SL, Onuki Y, Pakhlov P, Pakhlova G, Pal B, Park CW, Park H, Paul S, Pedlar TK, Pestotnik R, Petrič M, Piilonen LE, Pulvermacher C, Ritter M, Sakai Y, Sandilya S, Sanuki T, Savinov V, Schlüter T, Schneider O, Schnell G, Schwanda C, Seino Y, Semmler D, Senyo K, Seon O, Sevior ME, Shebalin V, Shibata TA, Shiu JG, Shwartz B, Simon F, Solovieva E, Starič M, Stypula J, Sumiyoshi T, Takizawa M, Tamponi U, Tanida K, Teramoto Y, Tikhomirov I, Trabelsi K, Uchida M, Uglov T, Unno Y, Uno S, Urquijo P, Usov Y, Van Hulse C, Varner G, Vorobyev V, Wang CH, Wang MZ, Wang P, Wang XL, Watanabe Y, Williams KM, Won E, Yamaoka J, Yamashita Y, Yelton J, Yuan CZ, Zhang ZP, Zhilich V, Zhukova V, Zhulanov V, Zupanc A. Energy Scan of the e^{+}e^{-}→h_{b}(nP)π^{+}π^{-} (n=1, 2) Cross Sections and Evidence for ϒ(11020) Decays into Charged Bottomoniumlike States. PHYSICAL REVIEW LETTERS 2016; 117:142001. [PMID: 27740802 DOI: 10.1103/physrevlett.117.142001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Indexed: 06/06/2023]
Abstract
Using data collected with the Belle detector at the KEKB asymmetric-energy e^{+}e^{-} collider, we measure the energy dependence of the e^{+}e^{-}→h_{b}(nP)π^{+}π^{-} (n=1, 2) cross sections from thresholds up to 11.02 GeV. We find clear ϒ(10860) and ϒ(11020) peaks with little or no continuum contribution. We study the resonant substructure of the ϒ(11020)→h_{b}(nP)π^{+}π^{-} transitions and find evidence that they proceed entirely via the intermediate isovector states Z_{b}(10610) and Z_{b}(10650). The relative fraction of these states is loosely constrained by the current data: The hypothesis that only Z_{b}(10610) is produced is excluded at the level of 3.3 standard deviations, while the hypothesis that only Z_{b}(10650) is produced is not excluded at a significant level.
Collapse
|
30
|
Pal B, Mangion P, Hossain MA, Wallace AS, Diffey BL. Should diuretics be prescribed for idiopathic carpal tunnel syndrome? Results of a controlled trial. Clin Rehabil 2016. [DOI: 10.1177/026921558800200405] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Diuretics are often prescribed to treat carpal tunnel syndrome (CTS) but their beneficial effect is unproven. In this double-blind controlled trial of bendrofluazide given for one month in 48 patients with the idiopathic CTS, treated and control patients showed similar clinical improvement, but the treated group showed more improvement than controls on electrophysiological tests. We conclude that bendrofluazide 5mgm daily for one month does not confer additional clinical benefit in the idiopathic CTS, but further trials with stronger diuretics and/or longer periods of treatment are warranted.
Collapse
|
31
|
Yang SB, Tanida K, Kim BH, Adachi I, Aihara H, Asner DM, Aulchenko V, Aushev T, Babu V, Badhrees I, Bakich AM, Barberio E, Bhardwaj V, Bhuyan B, Biswal J, Bonvicini G, Bozek A, Bračko M, Browder TE, Červenkov D, Chekelian V, Chen A, Cheon BG, Chilikin K, Chistov R, Cho K, Chobanova V, Choi Y, Cinabro D, Dalseno J, Danilov M, Dash N, Doležal Z, Drásal Z, Dutta D, Eidelman S, Farhat H, Fast JE, Ferber T, Fulsom BG, Gabyshev N, Garmash A, Gaur V, Gillard R, Goh YM, Goldenzweig P, Greenwald D, Grygier J, Haba J, Hamer P, Hara T, Hayasaka K, Hayashii H, Hou WS, Iijima T, Inami K, Inguglia G, Ishikawa A, Itoh R, Iwasaki Y, Jacobs WW, Jaegle I, Jeon HB, Joo KK, Julius T, Kang KH, Kato E, Katrenko P, Kiesling C, Kim DY, Kim HJ, Kim JB, Kim KT, Kim MJ, Kim SH, Kim SK, Kim YJ, Kinoshita K, Kobayashi N, Kodyš P, Korpar S, Križan P, Krokovny P, Kuhr T, Kuzmin A, Kwon YJ, Lange JS, Lee IS, Li CH, Li H, Li L, Li Y, Li Gioi L, Libby J, Liventsev D, Lubej M, Masuda M, Matvienko D, Miyabayashi K, Miyata H, Mizuk R, Mohanty GB, Moll A, Moon HK, Mussa R, Nakano E, Nakao M, Nanut T, Nath KJ, Nayak M, Negishi K, Niiyama M, Nisar NK, Nishida S, Ogawa S, Okuno S, Olsen SL, Pakhlova G, Pal B, Park CW, Park H, Pedlar TK, Pestotnik R, Petrič M, Piilonen LE, Pulvermacher C, Rauch J, Ritter M, Rostomyan A, Ryu S, Sahoo H, Sakai Y, Sandilya S, Santelj L, Sanuki T, Sato Y, Savinov V, Schlüter T, Schneider O, Schnell G, Schwanda C, Schwartz AJ, Seino Y, Senyo K, Seon O, Seong IS, Sevior ME, Shebalin V, Shibata TA, Shiu JG, Shwartz B, Simon F, Sohn YS, Sokolov A, Stanič S, Starič M, Stypula J, Sumihama M, Sumiyoshi T, Takizawa M, Tamponi U, Teramoto Y, Trabelsi K, Trusov V, Uchida M, Uglov T, Unno Y, Uno S, Urquijo P, Usov Y, Vanhoefer P, Varner G, Varvell KE, Vinokurova A, Vossen A, Wagner MN, Wang CH, Wang MZ, Wang P, Wang XL, Watanabe Y, Williams KM, Won E, Yamaoka J, Yashchenko S, Ye H, Yelton J, Yuan CZ, Yusa Y, Zhang ZP, Zhilich V, Zhulanov V, Zupanc A. First Observation of the Doubly Cabibbo-Suppressed Decay of a Charmed Baryon: Λ_{c}^{+}→pK^{+}π^{-}. PHYSICAL REVIEW LETTERS 2016; 117:011801. [PMID: 27419562 DOI: 10.1103/physrevlett.117.011801] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/24/2015] [Indexed: 06/06/2023]
Abstract
We report the first observation of the decay Λ_{c}^{+}→pK^{+}π^{-} using a 980 fb^{-1} data sample collected by the Belle detector at the KEKB asymmetric-energy e^{+}e^{-} collider. This is the first observation of a doubly Cabibbo-suppressed decay of a charmed baryon. We measure the branching ratio of this decay with respect to its Cabibbo-favored counterpart to be B(Λ_{c}^{+}→pK^{+}π^{-})/B(Λ_{c}^{+}→pK^{-}π^{+})=(2.35±0.27±0.21)×10^{-3}, where the uncertainties are statistical and systematic, respectively.
Collapse
|
32
|
Garmash A, Abdesselam A, Adachi I, Aihara H, Asner DM, Aushev T, Ayad R, Aziz T, Babu V, Badhrees I, Bakich AM, Behera P, Bhardwaj V, Bhuyan B, Bobrov A, Bondar A, Bonvicini G, Bozek A, Bračko M, Browder TE, Červenkov D, Chekelian V, Chen A, Cheon BG, Chilikin K, Cho K, Chobanova V, Choi Y, Cinabro D, Dalseno J, Danilov M, Dash N, Doležal Z, Drutskoy A, Dutta D, Eidelman S, Epifanov D, Farhat H, Fast JE, Ferber T, Fulsom BG, Gaur V, Gabyshev N, Gillard R, Goh YM, Goldenzweig P, Golob B, Hara T, Hayasaka K, Hayashii H, Iijima T, Ishikawa A, Itoh R, Iwasaki Y, Jaegle I, Joffe D, Joo KK, Julius T, Kang KH, Kato E, Kawasaki T, Kim DY, Kim JB, Kim KT, Kim MJ, Kim SH, Kim YJ, Kinoshita K, Korpar S, Križan P, Krokovny P, Kuhr T, Kuzmin A, Kwon YJ, Lange JS, Lee IS, Li C, Li H, Li L, Li Gioi L, Libby J, Liventsev D, Lukin P, Masuda M, Matvienko D, Miyabayashi K, Miyata H, Mizuk R, Mohanty GB, Moll A, Mori T, Mussa R, Nakano E, Nakao M, Nanut T, Natkaniec Z, Nishida S, Olsen SL, Pakhlov P, Pakhlova G, Pal B, Park H, Pedlar TK, Pestotnik R, Petrič M, Piilonen LE, Pulvermacher C, Ribežl E, Ritter M, Rostomyan A, Sahoo H, Sakai Y, Sandilya S, Sanuki T, Savinov V, Schneider O, Schnell G, Schwanda C, Seino Y, Semmler D, Senyo K, Seong IS, Sevior ME, Shebalin V, Shen CP, Shibata TA, Shiu JG, Shwartz B, Simon F, Sohn YS, Solovieva E, Starič M, Sumiyoshi T, Tamponi U, Tanida K, Teramoto Y, Trabelsi K, Uchida M, Uehara S, Uglov T, Uno S, Van Hulse C, Vanhoefer P, Varner G, Vorobyev V, Wagner MN, Wang CH, Wang MZ, Wang P, Watanabe Y, Williams KM, Won E, Yamamoto H, Yamaoka J, Yashchenko S, Yelton J, Yook Y, Yuan CZ, Zhang ZP, Zhilich V, Zhulanov V, Zupanc A. Observation of Z_{b}(10610) and Z_{b}(10650) Decaying to B Mesons. PHYSICAL REVIEW LETTERS 2016; 116:212001. [PMID: 27284649 DOI: 10.1103/physrevlett.116.212001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/25/2015] [Indexed: 06/06/2023]
Abstract
We report the analysis of the three-body e^{+}e^{-}→BB[over ¯]π^{±}, BB[over ¯]^{*}π^{±}, and B^{*}B[over ¯]^{*}π^{±} processes, including the first observations of the Z_{b}^{±}(10610)→[BB[over ¯]^{*}+c.c.]^{±} and Z_{b}^{±}(10650)→[B^{*}B[over ¯]^{*}]^{±} transitions that are found to dominate the corresponding final states. We measure Born cross sections for the three-body production of σ(e^{+}e^{-}→[BB[over ¯]^{*}+c.c.]^{±}π^{∓})=[17.4±1.6(stat)±1.9(syst)] pb and σ(e^{+}e^{-}→[B^{*}B[over ¯]^{*}]^{±}π^{∓})=[8.75±1.15(stat)±1.04(syst)] pb and set a 90% C.L. upper limit of σ(e^{+}e^{-}→[BB[over ¯]]^{±}π^{∓})<2.9 pb. The results are based on a 121.4 fb^{-1} data sample collected with the Belle detector at a center-of-mass energy near the ϒ(10860) peak.
Collapse
|
33
|
Pal B, Schwartz AJ, Abdesselam A, Adachi I, Aihara H, Asner DM, Aushev T, Ayad R, Aziz T, Babu V, Badhrees I, Bahinipati S, Bakich AM, Barberio E, Behera P, Bhardwaj V, Bhuyan B, Biswal J, Bobrov A, Bozek A, Bračko M, Browder TE, Červenkov D, Chekelian V, Chen A, Cheon BG, Chistov R, Cho K, Chobanova V, Choi Y, Cinabro D, Dalseno J, Dash N, Doležal Z, Drásal Z, Drutskoy A, Dutta D, Eidelman S, Farhat H, Fast JE, Fulsom BG, Gaur V, Garmash A, Gillard R, Goh YM, Goldenzweig P, Greenwald D, Grzymkowska O, Haba J, Hara T, Hayasaka K, Hayashii H, He XH, Hou WS, Inami K, Ishikawa A, Iwasaki Y, Jacobs WW, Jaegle I, Jeon HB, Joffe D, Joo KK, Julius T, Kang KH, Kato E, Kawasaki T, Kiesling C, Kim DY, Kim HJ, Kim KT, Kim MJ, Kim SH, Kinoshita K, Kodyš P, Korpar S, Križan P, Krokovny P, Kuhr T, Kumar R, Kumita T, Kuzmin A, Kwon YJ, Lee IS, Li CH, Li H, Li L, Li Gioi L, Libby J, Liventsev D, Lukin P, Luo T, Masuda M, Matvienko D, Miyabayashi K, Miyata H, Mizuk R, Mohanty GB, Mohanty S, Moll A, Moon HK, Mori T, Mussa R, Nakano E, Nakao M, Nanut T, Natkaniec Z, Nayak M, Nisar NK, Nishida S, Ogawa S, Okuno S, Pakhlov P, Pakhlova G, Park CW, Park H, Paul S, Pedlar TK, Pesántez L, Pestotnik R, Petrič M, Piilonen LE, Pulvermacher C, Rauch J, Ribežl E, Ritter M, Rostomyan A, Ryu S, Sahoo H, Sakai Y, Sandilya S, Sanuki T, Sato Y, Savinov V, Schlüter T, Schneider O, Schnell G, Schwanda C, Seino Y, Senyo K, Seon O, Seong IS, Shebalin V, Shibata TA, Shiu JG, Shwartz B, Simon F, Sohn YS, Sokolov A, Solovieva E, Stanič S, Starič M, Stypula J, Sumihama M, Sumiyoshi T, Tamponi U, Teramoto Y, Trabelsi K, Uchida M, Uehara S, Uglov T, Uno S, Urquijo P, Usov Y, Van Hulse C, Vanhoefer P, Varner G, Vinokurova A, Vossen A, Wagner MN, Wang CH, Wang MZ, Wang XL, Watanabe M, Watanabe Y, Williams KM, Won E, Yamaoka J, Yelton J, Yuan CZ, Yusa Y, Zhang ZP, Zhilich V, Zhulanov V, Zupanc A. Observation of the Decay B_{s}^{0}→K^{0}K[over ¯]^{0}. PHYSICAL REVIEW LETTERS 2016; 116:161801. [PMID: 27152790 DOI: 10.1103/physrevlett.116.161801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Indexed: 06/05/2023]
Abstract
We measure the decay B_{s}^{0}→K^{0}K[over ¯]^{0} using data collected at the ϒ(5S) resonance with the Belle detector at the KEKB e^{+}e^{-} collider. The data sample used corresponds to an integrated luminosity of 121.4 fb^{-1}. We measure a branching fraction B(B_{s}^{0}→K^{0}K[over ¯]^{0})=[19.6_{-5.1}^{+5.8}(stat)±1.0(syst)±2.0(N_{B_{s}^{0}B[over ¯]_{s}^{0}})]×10^{-6} with a significance of 5.1 standard deviations. This measurement constitutes the first observation of this decay.
Collapse
|
34
|
Lindeman GJ, Nolan E, Pal B, Vaillant F, Giner G, Whitehead L, Mann GB, Lok SW, Shackleton K, Smyth GK, Visvader JE. Abstract P3-11-05: RANK ligand is a target for breast cancer prevention in BRCA1 mutation carriers. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-11-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: BRCA1 mutation carriers often undergo prophylactic mastectomy to minimize their risk of breast cancer. The value of targeting ovarian hormones to prevent breast tumorigenesis remains contentious and the identification of an effective and acceptable chemoprevention strategy remains a 'holy grail' for the field. Recently, luminal progenitor cells have been identified as the likely cell-of-origin for BRCA1-associated breast tumors1. In addition, deregulated progesterone signaling has been implicated as a potential mechanism underlying tumor development in Brca1-deficient mammary glands2, although its role in luminal progenitor activation in BRCA1 mutation carriers is unknown. RANKL (Receptor Activator of Nuclear Factor-kappa B Ligand) has been identified as a key paracrine effector of progesterone-induced mammary epithelial proliferation in both mouse and human tissue3-5. Notably, RANKL and its receptor RANK play a critical role in the development of breast cancer, with inhibition of RANKL resulting in attenuation of tumorigenesis in mouse models of hormone-driven mammary carcinogenesis6,7.
Methods: We explored a role for the RANK/RANKL pathway during the preneoplastic phase in freshly isolated, histologically normal specimens from BRCA1 mutation carriers using a combination of strategies. RANK and RANKL expression in breast cancer was also evaluated in formalin fixed paraffin embedded (FFPE) archival sections by IHC. All samples were obtained with relevant IRB approval. A role for RANKL inhibition in attenuating tumor onset was studied using models that recapitulate human basal-like cancer.
Results: A RANK+ subset of luminal progenitor cells was identified in histologically normal breast tissue from BRCA1-mutation carriers. The RANK+ luminal progenitors exhibited higher proliferative activity compared to RANK- progenitors. RNA profiling revealed a distinctive molecular signature, consistent with the RANK+ subset being a possible target for neoplastic transformation. In established BRCA1-associated breast tumors, a four-fold higher incidence of RANK expression was observed, compared to tumors from non-carriers. In ongoing work, histologically normal pre-neoplastic BRCA1mut/+ tissue is being studied using ex vivo breast organoid assays to determine whether RANKL inhibition can attenuate breast epithelial proliferation.
Conclusions: Our data raise the possibility that RANK signaling is implicated in the initiation of tumorigenesis in BRCA1 mutation carriers (and possibly other high risk women) and that RANKL is a promising chemoprevention target. The findings are of sufficient interest to have led to a clinical trial, BRCA-D (Registered as ACTRN12614000694617). A finalized abstract will be submitted in early September, during the Late-Breaking Abstract submission period.
References:
1. Lim et al Nature Med 2009: 15, 907-13.
2. Poole et al Science 2006: 314, 1467-70.
3. Asselin-Labat et al Nature 2010: 465, 798-802.
4. Joshi et al Nature 2010: 465, 803-7.
5. Tanos et al Sci Transl Med 2013: 5, 182ra55.
6. Schramek et al Nature 2010: 468, 98-102.
7. Gonzales-Suarez et al Nature 2010: 468, 103-7.
Citation Format: Lindeman GJ, Nolan E, Pal B, Vaillant F, Giner G, Whitehead L, Mann GB, Lok SW, Shackleton K, Kathleen Cuningham Foundation Consortium (kConFab), Smyth GK, Visvader JE. RANK ligand is a target for breast cancer prevention in BRCA1 mutation carriers. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-11-05.
Collapse
|
35
|
Goswami J, Mallik S, Kumar G, Pal B, Das S. 276P Once-weekly high dose rate interstitial brachytherapy for carcinoma cervix is convenient, effective & well-tolerated. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv525.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Chang YY, Wang MZ, Abdesselam A, Adachi I, Adamczyk K, Aihara H, Al Said S, Asner DM, Atmacan H, Aushev T, Babu V, Badhrees I, Bakich AM, Barberio E, Bhuyan B, Biswal J, Bobrov A, Bozek A, Bračko M, Browder TE, Červenkov D, Chekelian V, Chen A, Cheon BG, Chilikin K, Chistov R, Chobanova V, Choi SK, Choi Y, Cinabro D, Dalseno J, Danilov M, Dingfelder J, Doležal Z, Drásal Z, Dutta D, Eidelman S, Farhat H, Fast JE, Ferber T, Fulsom BG, Gaur V, Gabyshev N, Ganguly S, Garmash A, Gillard R, Glattauer R, Goh YM, Goldenzweig P, Greenwald D, Grzymkowska O, Haba J, Hayasaka K, Hayashii H, He XH, Hou WS, Hsu CL, Iijima T, Inami K, Ishikawa A, Itoh R, Iwasaki Y, Jacobs WW, Jaegle I, Joffe D, Joo KK, Kawasaki T, Kim DY, Kim HJ, Kim JB, Kim JH, Kim KT, Kim MJ, Kim SH, Kim YJ, Kinoshita K, Korpar S, Križan P, Krokovny P, Kuhr T, Kumita T, Kuzmin A, Kwon YJ, Lai YT, Lee IS, Li L, Li Y, Libby J, Liventsev D, Lukin P, Masuda M, Matvienko D, Miyabayashi K, Miyake H, Miyata H, Mizuk R, Mohanty GB, Mohanty S, Moll A, Moon HK, Mori T, Nakano E, Nakao M, Nanut T, Nayak M, Nishida S, Ogawa S, Ozaki H, Pakhlov P, Pakhlova G, Pal B, Park CW, Pedlar TK, Pestotnik R, Petrič M, Piilonen LE, Rauch J, Ribežl E, Ritter M, Rostomyan A, Ryu S, Sahoo H, Sakai Y, Sandilya S, Santelj L, Sanuki T, Savinov V, Schneider O, Schnell G, Schwanda C, Seino Y, Senyo K, Seong IS, Sevior ME, Shebalin V, Shen CP, Shibata TA, Shiu JG, Simon F, Sohn YS, Starič M, Stypula J, Sumihama M, Sumisawa K, Sumiyoshi T, Tamponi U, Tanida K, Teramoto Y, Uglov T, Unno Y, Uno S, Usov Y, Van Hulse C, Vanhoefer P, Varner G, Vorobyev V, Vossen A, Wagner MN, Wang CH, Wang P, Watanabe M, Watanabe Y, Williams KM, Won E, Yamaoka J, Yashchenko S, Yelton J, Yusa Y, Zhang ZP, Zhilich V, Zhulanov V, Zupanc A. Observation of B^{0}→pΛ[over ¯]D^{(*)-}. PHYSICAL REVIEW LETTERS 2015; 115:221803. [PMID: 26650291 DOI: 10.1103/physrevlett.115.221803] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/11/2015] [Indexed: 06/05/2023]
Abstract
We report the first observation of the decays B^{0}→pΛ[over ¯]D^{(*)-}. The data sample of 711 fb^{-1} used in this analysis corresponds to 772×10^{6} BB[over ¯] pairs, collected at the ϒ(4S) resonance by the Belle detector at the KEKB asymmetric-energy e^{+}e^{-} collider. We observe 19.8σ and 10.8σ excesses of events for the two decay modes and measure the branching fractions of B^{0}→pΛ[over ¯]D^{-} and B^{0}→pΛ[over ¯]D^{*-} to be (25.1±2.6±3.5)×10^{-6} and (33.6±6.3±4.4)×10^{-6}, respectively, where the first uncertainties are statistical and the second are systematic. These results are not compatible with the predictions based on the generalized factorization approach. In addition, a threshold enhancement in the dibaryon (pΛ[over ¯]) system is observed, consistent with that observed in similar B decays.
Collapse
|
37
|
Tamponi U, Mussa R, Abdesselam A, Aihara H, Arinstein K, Asner DM, Atmacan H, Aushev T, Ayad R, Badhrees I, Bakich AM, Barberio E, Bhardwaj V, Bhuyan B, Biswal J, Bondar A, Bonvicini G, Bozek A, Bračko M, Browder TE, Červenkov D, Chen A, Cheon BG, Cho K, Chobanova V, Choi SK, Choi Y, Cinabro D, Danilov M, Doležal Z, Drásal Z, Drutskoy A, Eidelman S, Epifanov D, Farhat H, Fast JE, Ferber T, Fulsom BG, Gaur V, Gabyshev N, Garmash A, Getzkow D, Gillard R, Goh YM, Golob B, Haba J, Hayasaka K, Hayashii H, He XH, Hedges MT, Hou WS, Iijima T, Inami K, Ishikawa A, Jaegle I, Joffe D, Julius T, Kato E, Katrenko P, Kichimi H, Kiesling C, Kim DY, Kim HJ, Kim JH, Kim KT, Kim SH, Kinoshita K, Kodyš P, Korpar S, Križan P, Krokovny P, Kumita T, Kuzmin A, Lange JS, Lewis P, Libby J, Lukin P, Matvienko D, Miyabayashi K, Miyata H, Mizuk R, Mohanty GB, Moll A, Mori T, Nakano E, Nakao M, Nanut T, Natkaniec Z, Nayak M, Nisar NK, Nishida S, Ogawa S, Okuno S, Olsen SL, Ostrowicz W, Oswald C, Pakhlova G, Pal B, Park H, Pedlar TK, Pesántez L, Pestotnik R, Petrič M, Piilonen LE, Ribežl E, Ritter M, Rostomyan A, Ryu S, Sakai Y, Sandilya S, Santelj L, Sanuki T, Sato Y, Savinov V, Schneider O, Schnell G, Schwanda C, Semmler D, Senyo K, Sevior ME, Shapkin M, Shebalin V, Shen CP, Shibata TA, Shiu JG, Shwartz B, Sibidanov A, Simon F, Sohn YS, Sokolov A, Starič M, Steder M, Stypula J, Tanida K, Teramoto Y, Trabelsi K, Uchida M, Uglov T, Unno Y, Uno S, Urquijo P, Van Hulse C, Vanhoefer P, Varner G, Vinokurova A, Vossen A, Wagner MN, Wang MZ, Wang XL, Watanabe Y, Williams KM, Won E, Yamaoka J, Yashchenko S, Zhang ZP, Zhilich V, Zhulanov V, Zupanc A. First Observation of the Hadronic Transition ϒ(4S)→ηh(b)(1P) and New Measurement of the h(b)(1P) and η(b)(1S) Parameters. PHYSICAL REVIEW LETTERS 2015; 115:142001. [PMID: 26551806 DOI: 10.1103/physrevlett.115.142001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Indexed: 06/05/2023]
Abstract
Using a sample of 771.6×10(6) ϒϒ(4S) decays collected by the Belle experiment at the KEKB e(+)e(-) collider, we observe, for the first time, the transition ϒ(4S)→ηh(b)(1P) with the branching fraction B[ϒ(4S)→ηh(b)(1P)]=(2.18±0.11±0.18)×10(-3) and we measure the h(b)(1P) mass M(h(b)(1P))=(9899.3±0.4±1.0) MeV/c(2), corresponding to the hyperfine (HF) splitting ΔM(HF)(1P)=(0.6±0.4±1.0) MeV/c(2). Using the transition h(b)(1P)→γη(b)(1S), we measure the η(b)(1S) mass M(η(b)(1S))=(9400.7±1.7±1.6) MeV/c(2), corresponding to ΔM(HF)(1S)=(59.6±1.7±1.6) MeV/c(2), the η(b)(1S) width Γ(η(b)(1S))=(8(-5)(+6)±5) MeV/c(2) and the branching fraction B[h(b)(1P)→γη(b)(1S)]=(56±8±4)%.
Collapse
|
38
|
Abdesselam A, Adachi I, Adametz A, Adye T, Ahmed H, Aihara H, Akar S, Alam MS, Albert J, Al Said S, Andreassen R, Angelini C, Anulli F, Arinstein K, Arnaud N, Asner DM, Aston D, Aulchenko V, Aushev T, Ayad R, Babu V, Badhrees I, Bahinipati S, Bakich AM, Band HR, Banerjee S, Barberio E, Bard DJ, Barlow RJ, Batignani G, Beaulieu A, Bellis M, Ben-Haim E, Bernard D, Bernlochner FU, Bettarini S, Bettoni D, Bevan AJ, Bhardwaj V, Bhuyan B, Bianchi F, Biasini M, Biswal J, Blinov VE, Bloom PC, Bobrov A, Bomben M, Bondar A, Bonneaud GR, Bonvicini G, Bozek A, Bozzi C, Bračko M, Briand H, Browder TE, Brown DN, Brown DN, Bünger C, Burchat PR, Buzykaev AR, Calabrese R, Calcaterra A, Calderini G, Carpinelli M, Cartaro C, Casarosa G, Cenci R, Červenkov D, Chang P, Chao DS, Chauveau J, Cheaib R, Chekelian V, Chen A, Chen C, Cheng CH, Cheon BG, Chilikin K, Chistov R, Cho K, Chobanova V, Choi HHF, Choi SK, Chrzaszcz M, Cibinetto G, Cinabro D, Cochran J, Coleman JP, Contri R, Convery MR, Cowan G, Cowan R, Cremaldi L, Dalseno J, Dasu S, Davier M, Davis CL, De Mori F, De Nardo G, Denig AG, Derkach D, de Sangro R, Dey B, Di Lodovico F, Dingfelder J, Dittrich S, Doležal Z, Dorfan J, Drásal Z, Drutskoy A, Druzhinin VP, Dubois-Felsmann GP, Dunwoodie W, Dutta D, Ebert M, Echenard B, Eidelman S, Eigen G, Eisner AM, Emery S, Ernst JA, Faccini R, Farhat H, Fast JE, Feindt M, Ferber T, Ferrarotto F, Ferroni F, Field RC, Filippi A, Finocchiaro G, Fioravanti E, Flood KT, Ford WT, Forti F, Franco Sevilla M, Fritsch M, Fry JR, Fulsom BG, Gabathuler E, Gabyshev N, Gamba D, Garmash A, Gary JW, Garzia I, Gaspero M, Gaur V, Gaz A, Gershon TJ, Getzkow D, Gillard R, Li Gioi L, Giorgi MA, Glattauer R, Godang R, Goh YM, Goldenzweig P, Golob B, Golubev VB, Gorodeisky R, Gradl W, Graham MT, Grauges E, Griessinger K, Gritsan AV, Grosdidier G, Grünberg O, Guttman N, Haba J, Hafner A, Hamilton B, Hara T, Harrison PF, Hast C, Hayasaka K, Hayashii H, Hearty C, He XH, Hess M, Hitlin DG, Hong TM, Honscheid K, Hou WS, Hsiung YB, Huard Z, Hutchcroft DE, Iijima T, Inguglia G, Innes WR, Ishikawa A, Itoh R, Iwasaki Y, Izen JM, Jaegle I, Jawahery A, Jessop CP, Joffe D, Joo KK, Julius T, Kang KH, Kass R, Kawasaki T, Kerth LT, Khan A, Kiesling C, Kim DY, Kim JB, Kim JH, Kim KT, Kim P, Kim SH, Kim YJ, King GJ, Kinoshita K, Ko BR, Koch H, Kodyš P, Kolomensky YG, Korpar S, Kovalskyi D, Kowalewski R, Kravchenko EA, Križan P, Krokovny P, Kuhr T, Kumar R, Kuzmin A, Kwon YJ, Lacker HM, Lafferty GD, Lanceri L, Lange DJ, Lankford AJ, Latham TE, Leddig T, Le Diberder F, Lee DH, Lee IS, Lee MJ, Lees JP, Leith DWGS, Leruste P, Lewczuk MJ, Lewis P, Libby J, Lockman WS, Long O, Lopes Pegna D, LoSecco JM, Lou XC, Lueck T, Luitz S, Lukin P, Luppi E, Lusiani A, Luth V, Lutz AM, Lynch G, MacFarlane DB, Malaescu B, Mallik U, Manoni E, Marchiori G, Margoni M, Martellotti S, Martinez-Vidal F, Masuda M, Mattison TS, Matvienko D, McKenna JA, Meadows BT, Miyabayashi K, Miyashita TS, Miyata H, Mizuk R, Mohanty GB, Moll A, Monge MR, Moon HK, Morandin M, Muller DR, Mussa R, Nakano E, Nakazawa H, Nakao M, Nanut T, Nayak M, Neal H, Neri N, Nisar NK, Nishida S, Nugent IM, Oberhof B, Ocariz J, Ogawa S, Okuno S, Olaiya EO, Olsen J, Ongmongkolkul P, Onorato G, Onuchin AP, Onuki Y, Ostrowicz W, Oyanguren A, Pakhlova G, Pakhlov P, Palano A, Pal B, Palombo F, Pan Y, Panduro Vazquez W, Paoloni E, Park CW, Park H, Passaggio S, Patel PM, Patrignani C, Patteri P, Payne DJ, Pedlar TK, Peimer DR, Peruzzi IM, Pesántez L, Pestotnik R, Petrič M, Piccolo M, Piemontese L, Piilonen LE, Pilloni A, Piredda G, Playfer S, Poireau V, Porter FC, Posocco M, Prasad V, Prell S, Prepost R, Puccio EMT, Pulliam T, Purohit MV, Pushpawela BG, Rama M, Randle-Conde A, Ratcliff BN, Raven G, Ribežl E, Richman JD, Ritchie JL, Rizzo G, Roberts DA, Robertson SH, Röhrken M, Roney JM, Roodman A, Rossi A, Rostomyan A, Rotondo M, Roudeau P, Sacco R, Sakai Y, Sandilya S, Santelj L, Santoro V, Sanuki T, Sato Y, Savinov V, Schindler RH, Schneider O, Schnell G, Schroeder T, Schubert KR, Schumm BA, Schwanda C, Schwartz AJ, Schwitters RF, Sciacca C, Seiden A, Sekula SJ, Senyo K, Seon O, Serednyakov SI, Sevior ME, Shapkin M, Shebalin V, Shen CP, Shibata TA, Shiu JG, Simard M, Simi G, Simon F, Simonetto F, Skovpen YI, Smith AJS, Smith JG, Snyder A, So RY, Sobie RJ, Soffer A, Sohn YS, Sokoloff MD, Sokolov A, Solodov EP, Solovieva E, Spaan B, Spanier SM, Starič M, Stocchi A, Stroili R, Stugu B, Su D, Sullivan MK, Sumihama M, Sumisawa K, Sumiyoshi T, Summers DJ, Sun L, Tamponi U, Taras P, Tasneem N, Teramoto Y, Tisserand V, Todyshev KY, Toki WH, Touramanis C, Trabelsi K, Tsuboyama T, Uchida M, Uglov T, Unno Y, Uno S, Usov Y, Uwer U, Vahsen SE, Van Hulse C, Vanhoefer P, Varner G, Vasseur G, Va'vra J, Verderi M, Vinokurova A, Vitale L, Vorobyev V, Voß C, Wagner MN, Wagner SR, Waldi R, Walsh JJ, Wang CH, Wang MZ, Wang P, Watanabe Y, West CA, Williams KM, Wilson FF, Wilson JR, Wisniewski WJ, Won E, Wormser G, Wright DM, Wu SL, Wulsin HW, Yamamoto H, Yamaoka J, Yashchenko S, Yuan CZ, Yusa Y, Zallo A, Zhang CC, Zhang ZP, Zhilich V, Zhulanov V, Zupanc A. First Observation of CP Violation in B[over ¯]^{0}→D_{CP}^{(*)}h^{0} Decays by a Combined Time-Dependent Analysis of BABAR and Belle Data. PHYSICAL REVIEW LETTERS 2015; 115:121604. [PMID: 26430984 DOI: 10.1103/physrevlett.115.121604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Indexed: 06/05/2023]
Abstract
We report a measurement of the time-dependent CP asymmetry of B[over ¯]^{0}→D_{CP}^{(*)}h^{0} decays, where the light neutral hadron h^{0} is a π^{0}, η, or ω meson, and the neutral D meson is reconstructed in the CP eigenstates K^{+}K^{-}, K_{S}^{0}π^{0}, or K_{S}^{0}ω. The measurement is performed combining the final data samples collected at the ϒ(4S) resonance by the BABAR and Belle experiments at the asymmetric-energy B factories PEP-II at SLAC and KEKB at KEK, respectively. The data samples contain (471±3)×10^{6} BB[over ¯] pairs recorded by the BABAR detector and (772±11)×10^{6} BB[over ¯] pairs recorded by the Belle detector. We measure the CP asymmetry parameters -η_{f}S=+0.66±0.10(stat)±0.06(syst) and C=-0.02±0.07(stat)±0.03(syst). These results correspond to the first observation of CP violation in B[over ¯]^{0}→D_{CP}^{(*)}h^{0} decays. The hypothesis of no mixing-induced CP violation is excluded in these decays at the level of 5.4 standard deviations.
Collapse
|
39
|
Severn PS, Symes R, Rajendram R, Pal B. Topiramate maculopathy secondary to dose titration: first reported case. Eye (Lond) 2015; 29:982-4. [DOI: 10.1038/eye.2015.45] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
40
|
Modi P, Pal B, Kumar S, Modi J, Saifee Y, Nagraj R, Qadri J, Sharmah A, Agrawal R, Modi M, Shah V, Kute V, Trivedi H. Laparoscopic Transplantation Following Transvaginal Insertion of the Kidney: Description of Technique and Outcome. Am J Transplant 2015; 15:1915-22. [PMID: 25809421 DOI: 10.1111/ajt.13224] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Revised: 01/15/2015] [Accepted: 01/16/2015] [Indexed: 01/25/2023]
Abstract
Laparoscopic kidney transplantation (LKT) is well accepted modality of treatment for ESRD patients at our center. Usually, the kidney is inserted through small Pfannenstiel incision. With the permission of the Internal Review Board, we carried out LKT in eight female recipients following insertion of the kidney through the vagina. The kidney was procured by the retroperitoneoscopic approach. Antibiotic prophylaxis was given. All cases were carried out successfully with immediate graft function and 100% graft and patient survival at 1 year of follow-up. Estimated glomerular filtration rate at 1 month and 1 year was similar to eight randomly selected female recipients who underwent open kidney transplantation (OKT). No analgesia was required in seven out of eight patients after the 3rd postoperative day. In summary, vaginal insertion of kidney and LKT is safe and feasible in a selected group of patients. It is associated with better analgesia and has similar allograft function as compare to OKT.
Collapse
|
41
|
Marini C, Joseph B, Caramazza S, Capitani F, Bendele M, Mitrano M, Chermisi D, Mangialardo S, Pal B, Goyal M, Iadecola A, Mathon O, Pascarelli S, Sarma DD, Postorino P. Local disorder investigation in NiS(2-x)Se(x) using Raman and Ni K-edge x-ray absorption spectroscopies. JOURNAL OF PHYSICS. CONDENSED MATTER : AN INSTITUTE OF PHYSICS JOURNAL 2014; 26:452201. [PMID: 25320052 DOI: 10.1088/0953-8984/26/45/452201] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
We report on Raman and Ni K-edge x-ray absorption investigations of a NiS(2-x)Se(x) (with x = 0.00, 0.50/0.55, 0.60, and 1.20) pyrite family. The Ni K-edge absorption edge shows a systematic shift going from an insulating phase (x = 0.00 and 0.50) to a metallic phase (x = 0.60 and 1.20). The near-edge absorption features show a clear evolution with Se doping. The extended x-ray absorption fine structure data reveal the evolution of the local structure with Se doping which mainly governs the local disorder. We also describe the decomposition of the NiS(2-x)Se(x) Raman spectra and investigate the weights of various phonon modes using Gaussian and Lorentzian profiles. The effectiveness of the fitting models in describing the data is evaluated by means of Bayes factor estimation. The Raman analysis clearly demonstrates the disorder effects due to Se alloying in describing the phonon spectra of NiS(2-x)Se(x) pyrites.
Collapse
|
42
|
Lindeman GJ, Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ, Mann GB, Visvader JE. Abstract P2-09-01: Targeting BCL-2 with the BH3 mimetic ABT-199 in ER-positive breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-09-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Impairment of apoptosis is a hallmark of cancer and can result in resistance to therapy. Over-expression of the pro-survival protein BCL-2 is common in breast cancer, with elevated levels found in approximately 85% of luminal tumors. Although BCL-2 has been shown to be an important prognostic marker, its role as a therapeutic target has yet to be fully explored. Small molecule inhibitors termed ‘BH3 mimetics’ that mimic the action of pro-apoptotic BH3-only proteins have recently been developed. These bind and neutralize BCL-2 pro-survival proteins. We have previously shown that the BH3 mimetic ABT-737 (which neutralizes BCL-2, BCL-XL and BCL-W) synergizes with docetaxel in BCL-2-positive patient-derived xenograft (PDX) models. Recently, a potent BCL-2-specific inhibitor, ABT-199, has been developed that is showing considerable promise in early phase studies of lymphoid malignancies. Since BCL-2 expression is prominent in the luminal B tumors, we sought to determine whether it might be feasible to target luminal B tumors with combination therapy comprising endocrine therapy (tamoxifen) and a BH3 mimetic (ABT-737 or ABT-199), using novel PDX models of luminal B breast cancer.
Methods and Results: A panel of 36 primary breast tumor xenografts (including 15 luminal tumors) was generated in immunocompromised (NOG) mice. Three BCL-2-positive luminal B models (23T, 315T, 50T), as determined by Ki-67 immunostaining and gene expression profiling, and a control BCL-2-positive, ER-negative model (838T) were selected for further study. Cohorts of mice bearing tumor xenografts were treated with either ABT-737 (50 mg/kg i.p. d1-10), tamoxifen or both agents in q21d cycles. Tumor response and overall survival were significantly improved by combination therapy in all three ER-positive xenograft models, when compared to tamoxifen alone (p<0.005). Despite abundant BCL-XL expression in tumors, similar efficacy was observed with the selective BCL-2 inhibitor ABT-199 (50 mg/kg o.g. d1-5 and 8-12 q21d) and tamoxifen (p<0.005), revealing that BCL-2 is a crucial target. Unexpectedly, both BH3 mimetics were found to counteract the side effect of tamoxifen-induced endometrial hyperplasia. In addition, we observed that BH3 mimetics synergized with dual PI3K/mTOR inhibitors in the induction of apoptosis. In the 315T model, where AKT was found to be activated, triple therapy with ABT-737, a PI3K/mTOR inhibitor (PKI-587) and tamoxifen further augmented tumor response in vivo, when compared to ABT-737 and tamoxifen (p<0.004).
Discussion: Patient derived xenograft models of luminal B breast cancer have been derived that recapitulate the phenotype of the primary tumor. Here we have demonstrated that concomitant targeting of BCL-2 confers marked benefit above tamoxifen alone. Moreover, synergy between BH3 mimetics and PI3K/mTOR inhibitors could be exploited by targeting of both survival pathways, a strategy that appeared both safe and effective. Collectively, our findings provide a rationale for clinical evaluation of BH3 mimetics in early phase studies in breast cancer. Here, BCL-2 protein or mRNA expression (as determined by immunohistochemistry or RT-PCR, respectively) could provide a suitable companion biomarker for patient selection.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-09-01.
Collapse
|
43
|
Karampelas M, Kopsachilis N, Chang J, Pal B. Patient mit membranoproliferativer Glomerulonephritis Typ II. Ophthalmologe 2012; 109:791-3. [DOI: 10.1007/s00347-012-2550-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
44
|
Aaij R, Abellan Beteta C, Adeva B, Adinolfi M, Adrover C, Affolder A, Ajaltouni Z, Albrecht J, Alessio F, Alexander M, Alkhazov G, Alvarez Cartelle P, Alves AA, Amato S, Amhis Y, Anderson J, Appleby RB, Aquines Gutierrez O, Archilli F, Arrabito L, Artamonov A, Artuso M, Aslanides E, Auriemma G, Bachmann S, Back JJ, Bailey DS, Balagura V, Baldini W, Barlow RJ, Barschel C, Barsuk S, Barter W, Bates A, Bauer C, Bauer T, Bay A, Bediaga I, Belogurov S, Belous K, Belyaev I, Ben-Haim E, Benayoun M, Bencivenni G, Benson S, Benton J, Bernet R, Bettler MO, van Beuzekom M, Bien A, Bifani S, Bird T, Bizzeti A, Bjørnstad PM, Blake T, Blanc F, Blanks C, Blouw J, Blusk S, Bobrov A, Bocci V, Bondar A, Bondar N, Bonivento W, Borghi S, Borgia A, Bowcock TJV, Bozzi C, Brambach T, van den Brand J, Bressieux J, Brett D, Britsch M, Britton T, Brook NH, Brown H, Büchler-Germann A, Burducea I, Bursche A, Buytaert J, Cadeddu S, Callot O, Calvi M, Calvo Gomez M, Camboni A, Campana P, Carbone A, Carboni G, Cardinale R, Cardini A, Carson L, Carvalho Akiba K, Casse G, Cattaneo M, Cauet C, Charles M, Charpentier P, Chiapolini N, Ciba K, Cid Vidal X, Ciezarek G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Coca C, Coco V, Cogan J, Collins P, Comerma-Montells A, Constantin F, Contu A, Cook A, Coombes M, Corti G, Cowan GA, Currie R, D'Ambrosio C, David P, David PNY, De Bonis I, De Capua S, De Cian M, De Lorenzi F, De Miranda JM, De Paula L, De Simone P, Decamp D, Deckenhoff M, Degaudenzi H, Del Buono L, Deplano C, Derkach D, Deschamps O, Dettori F, Dickens J, Dijkstra H, Diniz Batista P, Domingo Bonal F, Donleavy S, Dordei F, Dosil Suárez A, Dossett D, Dovbnya A, Dupertuis F, Dzhelyadin R, Dziurda A, Easo S, Egede U, Egorychev V, Eidelman S, van Eijk D, Eisele F, Eisenhardt S, Ekelhof R, Eklund L, Elsasser C, Elsby D, Esperante Pereira D, Estève L, Falabella A, Fanchini E, Färber C, Fardell G, Farinelli C, Farry S, Fave V, Fernandez Albor V, Ferro-Luzzi M, Filippov S, Fitzpatrick C, Fontana M, Fontanelli F, Forty R, Frank M, Frei C, Frosini M, Furcas S, Gallas Torreira A, Galli D, Gandelman M, Gandini P, Gao Y, Garnier JC, Garofoli J, Garra Tico J, Garrido L, Gascon D, Gaspar C, Gauvin N, Gersabeck M, Gershon T, Ghez P, Gibson V, Gligorov VV, Göbel C, Golubkov D, Golutvin A, Gomes A, Gordon H, Grabalosa Gándara M, Graciani Diaz R, Granado Cardoso LA, Graugés E, Graziani G, Grecu A, Greening E, Gregson S, Gui B, Gushchin E, Guz Y, Gys T, Haefeli G, Haen C, Haines SC, Hampson T, Hansmann-Menzemer S, Harji R, Harnew N, Harrison J, Harrison PF, Hartmann T, He J, Heijne V, Hennessy K, Henrard P, Hernando Morata JA, van Herwijnen E, Hicks E, Holubyev K, Hopchev P, Hulsbergen W, Hunt P, Huse T, Huston RS, Hutchcroft D, Hynds D, Iakovenko V, Ilten P, Imong J, Jacobsson R, Jaeger A, Jahjah Hussein M, Jans E, Jansen F, Jaton P, Jean-Marie B, Jing F, John M, Johnson D, Jones CR, Jost B, Kaballo M, Kandybei S, Karacson M, Karbach TM, Keaveney J, Kenyon IR, Kerzel U, Ketel T, Keune A, Khanji B, Kim YM, Knecht M, Koppenburg P, Kozlinskiy A, Kravchuk L, Kreplin K, Kreps M, Krocker G, Krokovny P, Kruse F, Kruzelecki K, Kucharczyk M, Kvaratskheliya T, La Thi VN, Lacarrere D, Lafferty G, Lai A, Lambert D, Lambert RW, Lanciotti E, Lanfranchi G, Langenbruch C, Latham T, Lazzeroni C, Le Gac R, van Leerdam J, Lees JP, Lefèvre R, Leflat A, Lefrançois J, Leroy O, Lesiak T, Li L, Li Gioi L, Lieng M, Liles M, Lindner R, Linn C, Liu B, Liu G, von Loeben J, Lopes JH, Lopez Asamar E, Lopez-March N, Lu H, Luisier J, Mac Raighne A, Machefert F, Machikhiliyan IV, Maciuc F, Maev O, Magnin J, Malde S, Mamunur RMD, Manca G, Mancinelli G, Mangiafave N, Marconi U, Märki R, Marks J, Martellotti G, Martens A, Martin L, Martín Sánchez A, Martinez Santos D, Massafferri A, Mathe Z, Matteuzzi C, Matveev M, Maurice E, Maynard B, Mazurov A, McGregor G, McNulty R, Meissner M, Merk M, Merkel J, Messi R, Miglioranzi S, Milanes DA, Minard MN, Molina Rodriguez J, Monteil S, Moran D, Morawski P, Mountain R, Mous I, Muheim F, Müller K, Muresan R, Muryn B, Muster B, Musy M, Mylroie-Smith J, Naik P, Nakada T, Nandakumar R, Nasteva I, Nedos M, Needham M, Neufeld N, Nguyen-Mau C, Nicol M, Niess V, Nikitin N, Nomerotski A, Novoselov A, Oblakowska-Mucha A, Obraztsov V, Oggero S, Ogilvy S, Okhrimenko O, Oldeman R, Orlandea M, Otalora Goicochea JM, Owen P, Pal B, Palacios J, Palano A, Palutan M, Panman J, Papanestis A, Pappagallo M, Parkes C, Parkinson CJ, Passaleva G, Patel GD, Patel M, Paterson SK, Patrick GN, Patrignani C, Pavel-Nicorescu C, Pazos Alvarez A, Pellegrino A, Penso G, Pepe Altarelli M, Perazzini S, Perego DL, Perez Trigo E, Pérez-Calero Yzquierdo A, Perret P, Perrin-Terrin M, Pessina G, Petrella A, Petrolini A, Phan A, Picatoste Olloqui E, Pie Valls B, Pietrzyk B, Pilař T, Pinci D, Plackett R, Playfer S, Plo Casasus M, Polok G, Poluektov A, Polycarpo E, Popov D, Popovici B, Potterat C, Powell A, Prisciandaro J, Pugatch V, Puig Navarro A, Qian W, Rademacker JH, Rakotomiaramanana B, Rangel MS, Raniuk I, Raven G, Redford S, Reid MM, dos Reis AC, Ricciardi S, Rinnert K, Roa Romero DA, Robbe P, Rodrigues E, Rodrigues F, Rodriguez Perez P, Rogers GJ, Roiser S, Romanovsky V, Rosello M, Rouvinet J, Ruf T, Ruiz H, Sabatino G, Saborido Silva JJ, Sagidova N, Sail P, Saitta B, Salzmann C, Sannino M, Santacesaria R, Santamarina Rios C, Santinelli R, Santovetti E, Sapunov M, Sarti A, Satriano C, Satta A, Savrie M, Savrina D, Schaack P, Schiller M, Schleich S, Schlupp M, Schmelling M, Schmidt B, Schneider O, Schopper A, Schune MH, Schwemmer R, Sciascia B, Sciubba A, Seco M, Semennikov A, Senderowska K, Sepp I, Serra N, Serrano J, Seyfert P, Shapkin M, Shapoval I, Shatalov P, Shcheglov Y, Shears T, Shekhtman L, Shevchenko O, Shevchenko V, Shires A, Silva Coutinho R, Skwarnicki T, Smith AC, Smith NA, Smith E, Sobczak K, Soler FJP, Solomin A, Soomro F, Souza De Paula B, Spaan B, Sparkes A, Spradlin P, Stagni F, Stahl S, Steinkamp O, Stoica S, Stone S, Storaci B, Straticiuc M, Straumann U, Subbiah VK, Swientek S, Szczekowski M, Szczypka P, Szumlak T, T'Jampens S, Teodorescu E, Teubert F, Thomas C, Thomas E, van Tilburg J, Tisserand V, Tobin M, Topp-Joergensen S, Torr N, Tournefier E, Tran MT, Tsaregorodtsev A, Tuning N, Ubeda Garcia M, Ukleja A, Urquijo P, Uwer U, Vagnoni V, Valenti G, Vazquez Gomez R, Vazquez Regueiro P, Vecchi S, Velthuis JJ, Veltri M, Viaud B, Videau I, Vilasis-Cardona X, Visniakov J, Vollhardt A, Volyanskyy D, Voong D, Vorobyev A, Voss H, Wandernoth S, Wang J, Ward DR, Watson NK, Webber AD, Websdale D, Whitehead M, Wiedner D, Wiggers L, Wilkinson G, Williams MP, Williams M, Wilson FF, Wishahi J, Witek M, Witzeling W, Wotton SA, Wyllie K, Xie Y, Xing F, Xing Z, Yang Z, Young R, Yushchenko O, Zavertyaev M, Zhang F, Zhang L, Zhang WC, Zhang Y, Zhelezov A, Zhong L, Zverev E, Zvyagin A. Observation of B(s)(0) → J/ψf(2)'(1525) in J/ψK+ K- final states. PHYSICAL REVIEW LETTERS 2012; 108:151801. [PMID: 22587241 DOI: 10.1103/physrevlett.108.151801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2011] [Indexed: 05/31/2023]
Abstract
The decay B(s)(0) → J/ψK+ K- is investigated using 0.16 fb(-1) of data collected with the LHCb detector using 7 TeV pp collisions. Although the J/ψϕ channel is well known, final states at higher K+ K- masses have not previously been studied. In the K+ K- mass spectrum we observe a significant signal in the f(2)'(1525) region as well as a nonresonant component. After subtracting the nonresonant component, we find B(B(s)(0) → J/ψf(2)'(1525))/B(B(s)(0) → J/ψϕ) = (26.4 ± 2.7 ± 2.4)%.
Collapse
|
45
|
Aaij R, Adeva B, Adinolfi M, Adrover C, Affolder A, Ajaltouni Z, Albrecht J, Alessio F, Alexander M, Alkhazov G, Alvarez Cartelle P, Alves AA, Amato S, Amhis Y, Amoraal J, Anderson J, Appleby RB, Gutierrez OA, Arrabito L, Artamonov A, Artuso M, Aslanides E, Auriemma G, Bachmann S, Back JJ, Bailey DS, Balagura V, Baldini W, Barlow RJ, Barschel C, Barsuk S, Barter W, Bates A, Bauer C, Bauer T, Bay A, Bediaga I, Belous K, Belyaev I, Ben-Haim E, Benayoun M, Bencivenni G, Benson S, Benton J, Bernet R, Bettler MO, van Beuzekom M, Bien A, Bifani S, Bizzeti A, Bjørnstad PM, Blake T, Blanc F, Blanks C, Blouw J, Blusk S, Bobrov A, Bocci V, Bondar A, Bondar N, Bonivento W, Borghi S, Borgia A, Bowcock TJV, Bozzi C, Brambach T, van den Brand J, Bressieux J, Brisbane S, Britsch M, Britton T, Brook NH, Büchler-Germann A, Bursche A, Buytaert J, Cadeddu S, Carvajal JMC, Callot O, Calvi M, Gomez MC, Camboni A, Campana P, Carbone A, Carboni G, Cardinale R, Cardini A, Carson L, Akiba KC, Casse G, Cattaneo M, Charles M, Charpentier P, Chiapolini N, Vidal XC, Clarke PEL, Clemencic M, Cliff HV, Closier J, Coca C, Coco V, Cogan J, Collins P, Constantin F, Conti G, Contu A, Cook A, Coombes M, Corti G, Cowan GA, Currie R, D'Almagne B, D'Ambrosio C, David P, David PNY, De Bonis I, De Capua S, De Cian M, De Lorenzi F, De Miranda JM, De Paula L, De Simone P, Decamp D, Deckenhoff M, Degaudenzi H, Deissenroth M, Del Buono L, Deplano C, Deschamps O, Dettori F, Dickens J, Dijkstra H, Batista PD, Dossett D, Dovbnya A, Dupertuis F, Dzhelyadin R, Eames C, Easo S, Egede U, Egorychev V, Eidelman S, van Eijk D, Eisele F, Eisenhardt S, Ekelhof R, Eklund L, Elsasser C, d'Enterria DG, Pereira DE, Estève L, Falabella A, Fanchini E, Färber C, Fardell G, Farinelli C, Farry S, Fave V, Albor VF, Ferro-Luzzi M, Filippov S, Fitzpatrick C, Fontana M, Fontanelli F, Forty R, Frank M, Frei C, Frosini M, Furcas S, Torreira AG, Galli D, Gandelman M, Gandini P, Gao Y, Garnier JC, Garofoli J, Garrido L, Gaspar C, Gauvin N, Gersabeck M, Gershon T, Ghez P, Gibson V, Gligorov VV, Göbel C, Golubkov D, Golutvin A, Gomes A, Gordon H, Gándara MG, Diaz RG, Cardoso LAG, Graugés E, Graziani G, Grecu A, Gregson S, Gui B, Gushchin E, Guz Y, Gys T, Haefeli G, Haines SC, Hampson T, Hansmann-Menzemer S, Harji R, Harnew N, Harrison J, Harrison PF, He J, Heijne V, Hennessy K, Henrard P, Morata JAH, van Herwijnen E, Hofmann W, Holubyev K, Hopchev P, Hulsbergen W, Hunt P, Huse T, Huston RS, Hutchcroft D, Hynds D, Iakovenko V, Ilten P, Imong J, Jacobsson R, Hussein MJ, Jans E, Jansen F, Jaton P, Jean-Marie B, Jing F, John M, Johnson D, Jones CR, Jost B, Kandybei S, Karbach TM, Keaveney J, Kerzel U, Ketel T, Keune A, Khanji B, Kim YM, Knecht M, Koblitz S, Koppenburg P, Kozlinskiy A, Kravchuk L, Kreplin K, Krocker G, Krokovny P, Kruse F, Kruzelecki K, Kucharczyk M, Kukulak S, Kumar R, Kvaratskheliya T, La Thi VN, Lacarrere D, Lafferty G, Lai A, Lambert D, Lambert RW, Lanciotti E, Lanfranchi G, Langenbruch C, Latham T, Le Gac R, van Leerdam J, Lees JP, Lefèvre R, Leflat A, Lefrançois J, Leroy O, Lesiak T, Li L, Li YY, Li Gioi L, Lieng M, Lindner R, Linn C, Liu B, Liu G, Lopes JH, Asamar EL, Lopez-March N, Luisier J, Machefert F, Machikhiliyan IV, Maciuc F, Maev O, Magnin J, Maier A, Malde S, Mamunur RMD, Manca G, Mancinelli G, Mangiafave N, Marconi U, Märki R, Marks J, Martellotti G, Martens A, Martin L, Sánchez AM, Santos DM, Massafferri A, Mathe Z, Matteuzzi C, Matveev M, Maurice E, Maynard B, Mazurov A, McGregor G, McNulty R, Mclean C, Meissner M, Merk M, Merkel J, Messi R, Miglioranzi S, Milanes DA, Minard MN, Monteil S, Moran D, Morawski P, Morris JV, Mountain R, Mous I, Muheim F, Müller K, Muresan R, Muryn B, Musy M, Naik P, Nakada T, Nandakumar R, Nardulli J, Nedos M, Needham M, Neufeld N, Nguyen-Mau C, Nicol M, Nies S, Niess V, Nikitin N, Oblakowska-Mucha A, Obraztsov V, Oggero S, Ogilvy S, Okhrimenko O, Oldeman R, Orlandea M, Goicochea JMO, Pal B, Palacios J, Palutan M, Panman J, Papanestis A, Pappagallo M, Parkes C, Parkinson CJ, Passaleva G, Patel GD, Patel M, Paterson SK, Patrick GN, Patrignani C, Pavel-Nicorescu C, Alvarez AP, Pellegrino A, Penso G, Altarelli MP, Perazzini S, Perego DL, Trigo EP, Yzquierdo APC, Perret P, Perrin-Terrin M, Pessina G, Petrella A, Petrolini A, Pie Valls B, Pietrzyk B, Pilar T, Pinci D, Plackett R, Playfer S, Plo Casasus M, Polok G, Poluektov A, Polycarpo E, Popov D, Popovici B, Potterat C, Powell A, du Pree T, Pugatch V, Navarro AP, Qian W, Rademacker JH, Rakotomiaramanana B, Raniuk I, Raven G, Redford S, Reid MM, dos Reis AC, Ricciardi S, Rinnert K, Roa Romero DA, Robbe P, Rodrigues E, Rodrigues F, Cobo CR, Perez PR, Rogers GJ, Romanovsky V, Rouvinet J, Ruf T, Ruiz H, Sabatino G, Silva JJS, Sagidova N, Sail P, Saitta B, Salzmann C, Sannino M, Santacesaria R, Santinelli R, Santovetti E, Sapunov M, Sarti A, Satriano C, Satta A, Savrie M, Savrina D, Schaack P, Schiller M, Schleich S, Schmelling M, Schmidt B, Schneider O, Schopper A, Schune MH, Schwemmer R, Sciubba A, Seco M, Semennikov A, Senderowska K, Serra N, Serrano J, Seyfert P, Shao B, Shapkin M, Shapoval I, Shatalov P, Shcheglov Y, Shears T, Shekhtman L, Shevchenko O, Shevchenko V, Shires A, Coutinho RS, Skottowe HP, Skwarnicki T, Smith AC, Smith NA, Sobczak K, Soler FJP, Solomin A, Soomro F, Souza De Paula B, Spaan B, Sparkes A, Spradlin P, Stagni F, Stahl S, Steinkamp O, Stoica S, Stone S, Storaci B, Straumann U, Styles N, Swientek S, Szczekowski M, Szczypka P, Szumlak T, T'jampens S, Teodorescu E, Teubert F, Thomas C, Thomas E, van Tilburg J, Tisserand V, Tobin M, Topp-Joergensen S, Tran MT, Tsaregorodtsev A, Tuning N, Ukleja A, Urquijo P, Uwer U, Vagnoni V, Valenti G, Gomez RV, Regueiro PV, Vecchi S, Velthuis JJ, Veltri M, Vervink K, Viaud B, Videau I, Vilasis-Cardona X, Visniakov J, Vollhardt A, Voong D, Vorobyev A, Voss H, Wacker K, Wandernoth S, Wang J, Ward DR, Webber AD, Websdale D, Whitehead M, Wiedner D, Wiggers L, Wilkinson G, Williams MP, Williams M, Wilson FF, Wishahi J, Witek M, Witzeling W, Wotton SA, Wyllie K, Xie Y, Xing F, Yang Z, Young R, Yushchenko O, Zavertyaev M, Zhang L, Zhang WC, Zhang Y, Zhelezov A, Zhong L, Zverev E, Zvyagin A. Determination of f(s)/f(d) for 7 TeV pp collisions and measurement of the B0→D-K+ branching fraction. PHYSICAL REVIEW LETTERS 2011; 107:211801. [PMID: 22181871 DOI: 10.1103/physrevlett.107.211801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2011] [Indexed: 05/31/2023]
Abstract
The relative abundance of the three decay modes B(0)→D(-)K(+), B(0)→D(-)π(+), and B(s)(0)→D(s)(-)π(+) produced in 7 TeV pp collisions at the LHC is determined from data corresponding to an integrated luminosity of 35 pb(-1). The branching fraction of B(0)→D(-)K(+) is found to be B(B(0)→D(-)K(+)) = (2.01 ± 0.18(stat) ± 0.14(syst)) × 10(-4). The ratio of fragmentation fractions f(s)/f(d) is determined through the relative abundance of B(s)(0)→D(s)(-)π(+) to B(0)→D(-)K(+) and B(0)→D(-)π(+), leading to f(s)/f(d) = 0.253 ± 0.017 ± 0.017 ± 0.020, where the uncertainties are statistical, systematic, and theoretical, respectively.
Collapse
|
46
|
Foreman MGG, Pal B, Merryfield WJ. Trends in upwelling and downwelling winds along the British Columbia shelf. ACTA ACUST UNITED AC 2011. [DOI: 10.1029/2011jc006995] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
47
|
Bandyopadhyay S, Das S, Baruah KK, Chakravarty P, Chakrabarty D, Sarkar T, Pal B, De S, Pan D, Bera AK, Bandyopadhyay S, Bhattacharya D. Detection of bovine herpesvirus 1 sequences in yaks (Bos grunniens) with keratoconjunctivitis, using a highly sensitive nested polymerase chain reaction. REV SCI TECH OIE 2011; 29:695-703. [PMID: 21309468 DOI: 10.20506/rst.29.3.2009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Thirty-seven yaks (Bos grunniens) with keratoconjunctivitis and 22 healthy yaks were used to investigate the role of bovine herpesvirus 1 (BoHV-1) in keratoconjunctivitis in yaks. Nucleic acid sequences of BoHV-1 glycoproteins B and E were detected in conjunctival swabs from all yaks with keratoconjunctivitis using a nested polymerase chain reaction (PCR). In 21 yaks, BoHV-1 sequences were detected along with Moraxella bovis (M. bovis) and Neisseria spp. The amplified BoHV-1 sequences were identical, and no nucleotide variation was observed when compared with a BoHV-1 reference strain using single-strand conformation polymorphism analysis of the amplified DNA sequences. Interestingly, BoHV-1 sequences could not be detected in samples from healthy yaks. However, conjunctival swabs from two healthy yaks (9.09%) yielded M. bovis and Neisseria spp. Samples from 35 yaks with keratoconjunctivitis showed positive reactions in an avidin biotin enzyme-linked immunosorbent assay for BoHV-1 antibodies; all the healthy yaks were seronegative. This is the first report of a possible association of BoHV-1 with keratoconjunctivitis in yaks.
Collapse
|
48
|
Modi P, Rizvi J, Pal B, Bharadwaj R, Trivedi P, Trivedi A, Patel K, Shah K, Vyas J, Sharma S, Shah K, Chauhan R, Trivedi H. Laparoscopic kidney transplantation: an initial experience. Am J Transplant 2011; 11:1320-4. [PMID: 21486384 DOI: 10.1111/j.1600-6143.2011.03512.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Laparoscopic donor nephrectomy has the advantages of less pain, early ambulation and shorter hospitalization compared to open donor nephrectomy. Kidney recipient surgery is, however, traditionally performed by open surgery. Our aim was to study feasibility and safety of laparoscopic kidney transplantation (LKT). After permission from Internal Review Board, LKT was performed in four patients. All kidneys were procured from deceased donors. Left kidney was used for LKT and transplanted in left iliac fossa while right kidney was used for standard open kidney transplantation (OKT). All transplantation procedures were performed successfully. Cold ischemia time varied between 4 h and 14 h. For LKT, mean time for anastomosis was 65 (range 62-72) min, mean operative time was 3.97 (range 3.5-5) h, mean blood loss was 131.25 mL (range 45-350) mL. Mean wound length was 7 cm in LKT group and 18.4 cm in OKT group. Delayed graft function was observed in one patient in each group. One patient was lost in OKT group due to posttransplant bacterial meningitis. At 6 months, both groups have comparable value of serum creatinine. In conclusion, LKT is technically feasible and safe. Long term outcome needs to be evaluated in a larger study.
Collapse
|
49
|
Shah K, Parikh M, Pal B, Modi P. Bilateral focal xanthogranulomatous pyelonephritis in a child presenting as complex cystic renal mass: a report on non-surgical treatment. Eur J Pediatr Surg 2011; 21:207-8. [PMID: 21480167 DOI: 10.1055/s-0031-1271811] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
50
|
Lindeman GJ, Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin JT, Visvader JE. Abstract S5-6: Steroid Hormone Regulation of Mammary Stem Cell Function. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-s5-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The ovarian hormones estrogen and progesterone profoundly influence breast cancer risk, underpinning the benefit of endocrine therapies in the treatment of breast cancer. Modulation of their effects through ovarian ablation or chemoprevention strategies also significantly decreases breast cancer incidence. Conversely, there is an increased risk of breast cancer associated with pregnancy in the short-term. The cellular mechanisms underlying these observations, however, are poorly defined. We and others recently isolated mammary epithelial populations enriched for mammary stem cells (MaSCs), committed luminal progenitor and mature luminal cells from both mouse and human mammary glands. Unexpectedly, MaSCs exhibited a receptor-negative phenotype for ERα , PR and ErbB2. Given the central important of estrogen and progesterone signaling to mammary gland development and cancer, we sought to determine whether these hormones could indirectly modulate MaSC function. Methods and Results: We utilized mouse models to directly study the effects of steroid hormones on the in vivo repopulating ability of MaSCs. Ovariectomy markedly diminished MaSC number and the extent of ductal outgrowth in vivo. The relative contribution of estrogen and progesterone to the regulation of MaSC activity was next examined using hormone pellets or antagonists. MaSC activity increased in animals treated with both estrogen and progesterone. Remarkably, even three weeks of treatment with the aromatase inhibitor letrozole was sufficient to reduce the MaSC pool. The outgrowth potential of these cells was again affected, suggesting that MaSCs retain a ‘memory’ of estrogen deprivation, perhaps through perturbation of their cycling status. Indeed, cell cycle analysis revealed an increase in the percentage of MaSC-enriched cells in G0/G1 in ovariectomized glands compared to controls. This was accompanied by a profound reduction in the expression of cell cycle genes including Cyclin D1.
We further evaluated the effect of the hormonal environment on MaSC function during pregnancy, where progesterone (and prolactin) have prominent roles. Pregnancy led to a transient 11-fold increase in MaSC numbers. This was accompanied by marked elevation in the expression of the progesterone target gene RANK ligand in luminal cells, together with its receptor RANK in the MaSC-containing population. To determine whether MaSC activity is in part mediated through paracrine signals from RANK ligand, inhibitors of RANK signaling were evaluated. Treatment of virgin or pregnant mice with an anti-RANK ligand monoclonal antibody in vivo significantly impaired the clonogenic activity of the MaSC-enriched but not luminal subpopulation.
Discussion: Despite lacking the steroid hormone receptors ERα and PR, MaSCs appear to be exquisitely sensitive to hormone signaling, presumably via paracrine signaling that includes the RANK signaling pathway. The augmented MaSC pool during pregnancy suggests a cellular basis for the short-term increase in breast cancer incidence following pregnancy. Our findings further indicate that breast cancer chemoprevention may in part be achieved through suppression of MaSC function. We speculate that inhibitors of RANK and other stem cell signaling pathways could represent potential chemoprevention agents.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr S5-6.
Collapse
|